Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Putluri, Nagireddy ^a,f   Shojaie, Ali ^b   Vasu, Vihas T ^a   Nalluri, Srilatha ^a   Vareed, Shaiju K ^a,f   Putluri, Vasanta ^a,f   Vivekanandan Giri, Anuradha ^c   Byun, Jeman ^c   Pennathur, Subramaniam ^c   Sana, Theodore R ^d   Fischer, Steven M ^d   Palapattu, Ganesh S ^e   Creighton, Chad J ^f   Michailidis, George ^b   Sreekumar, Arun ^a,f  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d AGILENT TECHNOLOGIES   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANDROGEN;

AMINO ACID ANALYSIS; AMINO ACID METABOLISM; AMINO ACID TRANSPORT; ARTICLE; CANCER CELL; CANCER TISSUE; CELL METABOLISM; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; METABOLOMICS; PROSTATE CANCER; PROTEIN METHYLATION; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; DRUG EFFECT; METABOLISM; METABOLOME; METHODOLOGY; METHYLATION; PATHOLOGY; PHENOTYPE; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

AMINO ACIDS; ANDROGENS; CELL LINE, TUMOR; HUMANS; MALE; METABOLOME; METABOLOMICS; METHYLATION; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PHENOTYPE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 79960597789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021417     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Huggins C, Hodges CV, (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232-240.
3. Petrylak DP, (2005) The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65: 3-7; discussion 7-8.
4. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
5. Scher HI, Sawyers CL, (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
6. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J, (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5: 1921-1930.
7. Montgomery JS, Price DK, Figg WD, (2001) The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146.
8. Monge A, Jagla M, Lapouge G, Sasorith S, Cruchant M, et al. (2006) Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci 63: 487-497.
9. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, et al. (1995) Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80: 3494-3500.
10. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, et al. (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864.
11. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, et al. (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669.
12. Lin B, White JT, Lu W, Xie T, Utleg AG, et al. (2005) Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 65: 3081-3091.
13. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, et al. (2004) Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 64: 347-355.
14. Meehan KL, Sadar MD, (2004) Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 4: 1116-1134.
15. Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, et al. (2000) Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis 21: 1823-1831.
16. Waghray A, Feroze F, Schober MS, Yao F, Wood C, et al. (2001) Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 1: 1327-1338.
17. Wright ME, Eng J, Sherman J, Hockenbery DM, Nelson PS, et al. (2003) Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol 5: R4.
18. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, et al. (2002) Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 3: RESEARCH0032.
19. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, et al. (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21: 8749-8758.
20. Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, et al. (2010) Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res 30: 3895-3901.
21. Kaarbo M, Mikkelsen OL, Malerod L, Qu S, Lobert VH, et al. (2010) PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 32: 11-27.
22. Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, et al. (2010) Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate 70: 866-874.
23. Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, et al. (2009) A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol 41: 603-614.
24. Feng Z, Levine AJ, (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20: 427-434.
25. Polak P, Hall MN, (2009) mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21: 209-218.
26. Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran T, Yu J, et al. (2009) Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One 4: e7075.
27. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
28. Sana TR, Waddell K, Fischer SM, (2008) A sample extraction and chromatographic strategy for increasing LC/MS detection coverage of the erythrocyte metabolome. J Chromatogr B Analyt Technol Biomed Life Sci 871: 314-321.
29. Strimmer K, (2008) fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 24: 1461-1462.
30. Efron B, Tibshirani R, (2007) On testing the significance of sets of genes. Ann Appl Stat 1: 107-129.
31. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
32. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, et al. (2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9: 443-454.
33. Vellaichamy A, Dezso Z, JeBailey L, Chinnaiyan AM, Sreekumar A, et al. (2010) "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One 5: e10936.
34. Schayek H, Bentov I, Sun S, Plymate SR, Werner H, (2010) Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res 316: 1479-1488.
35. Fernandez SV, Snider KE, Wu YZ, Russo IH, Plass C, et al. (2010) DNA methylation changes in a human cell model of breast cancer progression. Mutat Res 688: 28-35.
36. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, et al. (2008) DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 1: 47.
37. Kim HC, Roh SA, Ga IH, Kim JS, Yu CS, et al. (2005) CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J Gastroenterol Hepatol 20: 1920-1926.
38. Noda H, Kato Y, Yoshikawa H, Arai M, Togashi K, et al. (2005) Microsatellite instability caused by hMLH1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer. Oncology 69: 354-362.
39. Kamikihara T, Arima T, Kato K, Matsuda T, Kato H, et al. (2005) Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. Int J Cancer 115: 690-700.
40. Sharrard RM, Royds JA, Rogers S, Shorthouse AJ, (1992) Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer 65: 667-672.
41. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, et al. (2010) Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 9: 33-45.
42. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, et al. (2002) Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 94: 384-390.
43. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, et al. (2000) Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60: 3623-3630.
44. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, et al. (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58: 5310-5314.
45. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
46. Perry AS, Watson RW, Lawler M, Hollywood D, (2010) The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 7: 668-680.
47. Hurtubise A, Bernstein ML, Momparler RL, (2008) Preclinical evaluation of the antineoplastic action of 5-aza-2′-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 8: 16.